Here is the link https://endpts.com/watch-out-bluebird-a-little-biotech-just-got-novartis-backing-to-break-out-of-the-back-field-and-race-you-to-the-finish-line-with-a-bcma-car-t/
Poseida is using nonviral (piggyBac) manufacturing and the product is comprised primarily of early memory cells, mostly Tscm which are self-renewing and long-lived (these survive for decades). The company uses fully-human binders and other components which mean low or no immunogenicity, no tonic signaling or exhaustion. They are also working on allogeneic and for this Cas-CLOVER is used.
Three other INDs should happen later this year or 2020. Those include P-PSMA-101, an autologous candidate targeting PSMA; P-BCMA-ALLO1, an allo version for R/R multiple myeloma; and P-MUC1C-101 (again, allo), aimed at multiple solid tumor indications.